<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800956</url>
  </required_header>
  <id_info>
    <org_study_id>A6061018</org_study_id>
    <nct_id>NCT00800956</nct_id>
  </id_info>
  <brief_title>Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine</brief_title>
  <acronym>ADME</acronym>
  <official_title>An Open Label, Single Oral Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Esreboxetine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn more about how esreboxetine is handled by the body i.e.
      the absorption, metabolism and excretion of esreboxetine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative excretion of radioactivity in urine and and faeces as a percentage of the total radioactive dose administered over time. Collection of plasma, urine and faeces for the assessment of parent drug and metabolites of esreboxetine where possible</measure>
    <time_frame>Approx 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic parameters of esreboxetine and identification and abundance of metabolites in plasma, urine and faeces if possible</measure>
    <time_frame>Approx 10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical safety data</measure>
    <time_frame>Approx 10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of plasma esreboxetine metabolites if possible</measure>
    <time_frame>Approx 10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single oral dose of [14C]-esreboxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-esreboxetine</intervention_name>
    <description>Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine</description>
    <arm_group_label>Single oral dose of [14C]-esreboxetine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male subjects aged 45 to 65 years Body mass index (BMI=weight/height2) 18 to 30
        kg/m2

        Exclusion Criteria:

        Any clinically relevant abnormality identified on the screening medical assessment Any
        condition possibly affecting drug absorption Subjects with exposure to significant
        radiation (eg serial Xray or CT scans, barium meal etc)or who have participated in a
        radiolabelled study in the past 12 months, or who have occupational exposure to
        radioactivity History of regular alcohol consumption exceeding 14 drinks/week (1 drink =
        5ounces (150ml) of wine or 12 ounces (360ml) of beer or 1.5 ounces (45ml) of hard liquor)
        within 6 months of screening 12-lead ECG demonstrating QTc&gt;450mses at screening Treatment
        with an investigational drug within 30 days or 5 half-lives preceding the first dose of
        study medication
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A6061018&amp;StudyName=Phase%20I%20study%20to%20determine%20the%20absorption%2C%20distribution%2C%20metabolism%20and%20excretion%20of%20esreboxetine</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>April 6, 2011</last_update_submitted>
  <last_update_submitted_qc>April 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>Radiolabel ADME study Healthy volunteers</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

